Savontaus E, Rouru J, Boss O, Huupponen R, Koulu M
Department of Pharmacology and Clinical Pharmacology, University of Turku, Finland.
Biochem Biophys Res Commun. 1998 May 29;246(3):899-904. doi: 10.1006/bbrc.1998.8721.
The expressions of uncoupling proteins 2 and 3 (UCP2; UCP3) mRNA were studied in obese (fa/fa) Zucker rats treated with two weight gain reducing agents for three weeks. The specific beta 3-adrenoceptor agonist BRL 35135 (0.5 mg/kg/day orally) increased the expression of UCP3 mRNA by 3.8-fold (P < 0.0001; two-way ANOVA) and that of UCP1 mRNA by 2.6-fold (P = 0.014) in brown adipose tissue, but had no effect on expression of UCP3 mRNA in white fat or in the soleus muscle, or on UCP2 mRNA expression in brown or white fat. The antihyperglycemic metformin (300 mg/kg/day orally) had no effect on expressions of UCP1, UCP2 or UCP3 in any tissue studied. Concentrations of plasma insulin were significantly correlated with the levels of white fat UCP2 mRNA (in the control group: r = 0.89, P = 0.0015) and UCP3 mRNA (in the control group: r = 0.80, P = 0.009) suggesting that insulin may play a role in the control of UCP2 and UCP3 mRNA expressions in white adipose tissue.
研究了用两种体重增加抑制剂治疗三周的肥胖（fa/fa） Zucker大鼠中解偶联蛋白2和3（UCP2；UCP3）mRNA的表达情况。特异性β3 -肾上腺素能受体激动剂BRL 35135（0.5 mg/kg/天，口服）使棕色脂肪组织中UCP3 mRNA的表达增加了3.8倍（P < 0.0001；双向方差分析），UCP1 mRNA的表达增加了2.6倍（P = 0.014），但对白色脂肪或比目鱼肌中UCP3 mRNA的表达以及棕色或白色脂肪中UCP2 mRNA的表达没有影响。降糖药二甲双胍（300 mg/kg/天，口服）对所研究的任何组织中UCP1、UCP2或UCP3的表达均无影响。血浆胰岛素浓度与白色脂肪UCP2 mRNA水平（对照组：r = 0.89，P = 0.0015）和UCP3 mRNA水平（对照组：r = 0.80，P = 0.009）显著相关，提示胰岛素可能在白色脂肪组织中UCP2和UCP3 mRNA表达的调控中发挥作用。
